SEC Form 6-K filed by Redhill Biopharma Ltd.

$RDHL
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $RDHL alert in real time by email
6-K 1 zk2532922.htm 6-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 6-K
  
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
 
For the month of March 2025
Commission File No.:001-35773
 
REDHILL BIOPHARMA LTD.
(Translation of registrant’s name into English)
 
21 Ha’arba’a Street, Tel Aviv, 6473921, Israel
(Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  

Form 20-F ☒        Form 40-F ☐
 
Attached hereto and incorporated herein by reference is the notice of the annual general meeting of RedHill Biopharma Ltd. scheduled for May 5, 2025.

This Form 6-K is hereby incorporated by reference into the Company’s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001), on June 20, 2024 (File No. 333-280327) and on March 25, 2025 (File No. 333-286082), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), August 4, 2023 (File No. 333-273709) and on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
REDHILL BIOPHARMA LTD.
 
 
(the “Registrant”)
 
 
 
 
 
Date: March 26, 2025
By:
/s/ Dror Ben-Asher
 
 
Name:
Dror Ben-Asher
 
 
Title:
Chief Executive Officer
 



REDHILL BIOPHARMA LTD.
21 Ha’arba’a Street
Tel-Aviv 6473921
Israel

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
To be held on May 5, 2025

The Annual General Meeting of Shareholders of RedHill Biopharma Ltd. (the “Company”), will be held at the offices of the Company, 21 Ha’arba’a Street, 16th Floor, Tel-Aviv, Israel, on May 5, 2025, at 3:00 p.m. Israel time, or at any adjournments thereof (the “General Meeting”), for the following purposes:
 

1.
To appoint Kesselman & Kesselman, certified public accountants in Israel and a member of PricewaterhouseCoopers International Limited, as the Company’s auditors for the year 2025 and for an additional period until the next Annual General Meeting; and to inform the shareholders of the aggregate compensation paid to the auditors for the year ended December 31, 2024;
 

2.
To approve the re-election of Mr. Dror Ben-Asher and Dr. Kenneth Reed to the board of directors of the Company (the “Board of Directors”) for an additional three-year term until the annual general meeting to be held in 2028;
 

3.
To approve a renewal of an amended version of the Company’s compensation policy (the “Compensation Policy”) for a three-year period in accordance with the requirements of the Israeli Companies Law, 5759-1999;
 

4.
To approve the grant of restricted share units (“RSUs”) each with respect to one American Depository Share (each representing 10,000 ordinary shares, par value NIS 0.01 each) (“ADSs”) to the non-executive directors of the Company;
 

5.
To approve the grant of RSUs to Mr. Dror Ben-Asher, the Company’s Chief Executive Officer and Chairman of the Board of Directors;
 

6.
To approve a grant of RSUs of the Company to Mr. Rick D. Scruggs, the Company’s Chief Commercial Officer, and Director; and
 

7.
To approve an increase in the Company’s authorized share capital.

In addition, shareholders at the General Meeting will have an opportunity to review and ask questions regarding the financial statements of the Company for the fiscal year ended December 31, 2024.
 
The Company is currently unaware of any other matters that may be raised at the General Meeting. Should any other matters be properly raised at the General Meeting, the persons designated as proxies shall vote according to their own judgment on those matters.
 
Only holders of record of ADSs, evidenced by American Depositary Receipts issued by The Bank of New York Mellon at the close of business on March 27, 2025, shall be entitled to receive notice of and to vote at the General Meeting.
 
The Board of Directors recommends that you vote “FOR” the proposals, as specified on the enclosed form of proxy.
 
ADS holders should return their proxies by the date set forth on their form of proxy.
 
Shareholders wishing to express their position on an agenda item for this General Meeting may do so by submitting a written statement (“Position Statement”) to the Company’s offices, c/o Mr. Razi Ingber, at 21 Ha’arba’a Street, Tel-Aviv, 6473921 Israel, by no later than April 25, 2025. Any Position Statement received, that is in accordance with the guidelines set by the Israel Companies Law, will be furnished to the U.S. Securities and Exchange Commission (the “Commission”) on Form 6-K, and will be made available to the public on the Commission’s website at http://www.sec.gov.
 
 If within half an hour from the time appointed for the General Meeting, a quorum is not present, the General Meeting shall be adjourned to the next business day following the day of the scheduled General Meeting, at the same time and place, or at another day, time and place prescribed by the Board of Directors in a notification to the shareholders.

This Notice and the documents mentioned therein, as well as the proposed resolutions on the agenda, will be made available to the public on the Company's website http://www.redhillbio.com and on the Commission’s website at http://www.sec.gov.
 
 
By Order of the Board of Directors,
 
Dror Ben-Asher
 
Chairman of the Board of Directors

Tel-Aviv, Israel
March 26, 2025


Get the next $RDHL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RDHL

DatePrice TargetRatingAnalyst
9/15/2021$23.00 → $21.00Buy
HC Wainwright & Co.
8/31/2021$22.00Overweight
Cantor Fitzgerald
More analyst ratings

$RDHL
Press Releases

Fastest customizable press release news feed in the world

See more
  • RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

    RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK approval in Q4/25 Listed by ACG3 Clinical Guideline as a first-line option, Talicia is the leading branded H. pylori therapy prescribed by U.S. gastroenterologists and the only FDA-approved all-in-one, low-dose rifabutin-based therapy designed to address H. pylori resistance to other antibiotics Talicia is also approved and launched in the UAE4 and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes H. pylori infection is a billion-dollar market opportunity affecting approximate

    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

    The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn's Disease (CD) patients who are all MAP-positive, and will correlate mucosal healing with MAP2 infection eradication utilizing novel endpoints and imaging, pending Type C discussions on path to FDA approval, with FDA guidance expected in Q2/25 -- Patent protected until 2041, RHB-204 is a next generation anti-MAP therapy derivative of RHB-1043 which successfully met its groundbreaking Phase 3 study primary and secondary endpoints demonstrating a statistically significant 64% improvement in efficacy versus SoC and showed compelling mucosal healing data in CD patients who underwent colonoscopy. The i

    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

    Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the European Life Sciences CEO Forum The update covers: The recent out-licensing of RHB-102[1] to Hyloris (Euronext Brussels: HYL) in a potential $60 million plus royalties dealInitiation of the Bayer-funded Phase 2 clinical study of opaganib[2] in combination with Bayer's (ETR: BAYN) darolutamide in advanced prostate cancerStatus of the U.S. government-supported pipeline programs and expected 2025 catalystsSignificant commercial progress with Talicia®:Additional marketing authorization applications in new markets being evaluatedDiscussions ongoing focused on significant cost of goods (COGs) reductionInclusio

    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RDHL
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RDHL
SEC Filings

See more

$RDHL
Leadership Updates

Live Leadership Updates

See more
  • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

    -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

    $ATNM
    $AVTX
    $RDHL
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RDHL
Financials

Live finance-specific insights

See more
  • RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

    Targeting positive cash from operations to start during H2/22[1] Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expected operational cost savings of approximately $50 million over the next 18 months Continuous implementation of disciplined cost controls reduced Q1/22 cash used in operating activities by more than 70% to approximately $4 million, compared to approximately $15 million in Q4/21 Net revenues of $18.2 million in Q1/22; Cash balance[2] of $45 million as of March 31, 2022 Talicia® TRx up 12.8% over Q4/21 and Movantik® continues strong Q4/21 prescription performance Amendment improves key covenants i

    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022

    TEL AVIV, Israel and RALEIGH, N.C., June 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022. The Company will host a conference call and webcast on Thursday, June 23, 2022, at 8:30 a.m. EDT, during which it will present key highlights for the first quarter of 2022. The webcast including slides will be broadcast live on the Company's website, https://ir.redhillbio.com/ev

    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial Results

    TEL AVIV, Israel and RALEIGH, N.C., March 17, 2022 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its operational highlights and financial results for the fourth quarter and full year ended December 31, 2021. Dror Ben-Asher, RedHill's Chief Executive Officer, said: "In 2021, RedHill's team delivered record revenues against a pandemic backdrop, overall contribution of commercial operations to the company was positive for the first time in Q4/21 and positive late-stage clinical data for two novel oral COVID-19 drugs. A very strong fourth quarter for both Talicia® and Movantik®, coupled with disciplined c

    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RDHL
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more